25 XP   0   0   10

Acorda Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Acorda together

PenkeI guess you are interested in Acorda Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Acorda Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Acorda Therapeutics Inc

I send you an email if I find something interesting about Acorda Therapeutics Inc.

Quick analysis of Acorda (30 sec.)










What can you expect buying and holding a share of Acorda? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.2%

What is your share worth?

Current worth
$47.47
Expected worth in 1 year
$33.93
How sure are you?
43.9%

+ What do you gain per year?

Total Gains per Share
$-13.53
Return On Investment
-113.6%

For what price can you sell your share?

Current Price per Share
$11.91
Expected price per share
$9.6 - $14.75
How sure are you?
50%

1. Valuation of Acorda (5 min.)




Live pricePrice per Share (EOD)

$11.91

Intrinsic Value Per Share

$-573.34 - $267.97

Total Value Per Share

$-525.88 - $315.43

2. Growth of Acorda (5 min.)




Is Acorda growing?

Current yearPrevious yearGrowGrow %
How rich?$58.9m$110.5m-$36.2m-48.7%

How much money is Acorda making?

Current yearPrevious yearGrowGrow %
Making money-$3.9m-$26.4m$22.4m562.2%
Net Profit Margin-19.6%-89.0%--

How much money comes from the company's main activities?

3. Financial Health of Acorda (5 min.)




What can you expect buying and holding a share of Acorda? (5 min.)

Welcome investor! Acorda's management wants to use your money to grow the business. In return you get a share of Acorda.

What can you expect buying and holding a share of Acorda?

First you should know what it really means to hold a share of Acorda. And how you can make/lose money.

Speculation

The Price per Share of Acorda is $11.91. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acorda.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acorda, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $47.47. Based on the TTM, the Book Value Change Per Share is $-3.38 per quarter. Based on the YOY, the Book Value Change Per Share is $-17.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acorda.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-7.16-60.1%-3.38-28.3%-21.26-178.5%-22.93-192.5%-14.97-125.7%
Usd Book Value Change Per Share-7.17-60.2%-3.38-28.4%-17.85-149.9%-21.72-182.4%-7.22-60.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.040.4%0.615.1%
Usd Total Gains Per Share-7.17-60.2%-3.38-28.4%-17.85-149.9%-21.68-182.0%-6.60-55.4%
Usd Price Per Share14.99-7.34-1.19-4.63-16.73-
Price to Earnings Ratio-0.52--0.24--0.02--0.04-1.21-
Price-to-Total Gains Ratio-2.09--0.97--0.09--0.24--0.21-
Price to Book Ratio0.32-0.15-0.01-0.04-0.05-
Price-to-Total Gains Ratio-2.09--0.97--0.09--0.24--0.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.91
Number of shares83
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-3.38-21.72
Usd Total Gains Per Share-3.38-21.68
Gains per Quarter (83 shares)-280.80-1,799.36
Gains per Year (83 shares)-1,123.22-7,197.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1123-113315-7212-7207
20-2246-225630-14425-14404
30-3370-337945-21637-21601
40-4493-450260-28849-28798
50-5616-562575-36062-35995
60-6739-674890-43274-43192
70-7863-7871104-50487-50389
80-8986-8994119-57699-57586
90-10109-10117134-64911-64783
100-11232-11240149-72124-71980

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%14.027.00.034.1%24.051.01.031.6%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%17.024.00.041.5%39.037.00.051.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%5.00.036.012.2%8.00.068.010.5%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%18.023.00.043.9%41.035.00.053.9%

Fundamentals of Acorda

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Fundamental data was last updated by Penke on 2024-03-20 08:42:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Acorda Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Acorda earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -32.1% means that $-0.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acorda Therapeutics Inc:

  • The MRQ is -32.1%. The company is making a huge loss. -2
  • The TTM is -19.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-32.1%TTM-19.6%-12.5%
TTM-19.6%YOY-89.0%+69.4%
TTM-19.6%5Y-77.9%+58.3%
5Y-77.9%10Y-40.6%-37.3%
1.1.2. Return on Assets

Shows how efficient Acorda is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2.4% Return on Assets means that Acorda generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acorda Therapeutics Inc:

  • The MRQ is -2.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM-1.2%-1.3%
TTM-1.2%YOY-6.3%+5.2%
TTM-1.2%5Y-4.4%+3.3%
5Y-4.4%10Y-2.5%-1.9%
1.1.3. Return on Equity

Shows how efficient Acorda is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • -15.1% Return on Equity means Acorda generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acorda Therapeutics Inc:

  • The MRQ is -15.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.1%TTM-7.6%-7.5%
TTM-7.6%YOY-26.1%+18.5%
TTM-7.6%5Y-15.2%+7.6%
5Y-15.2%10Y-8.3%-7.0%

1.2. Operating Efficiency of Acorda Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Acorda is operating .

  • Measures how much profit Acorda makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -26.4% means the company generated $-0.26  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acorda Therapeutics Inc:

  • The MRQ is -26.4%. The company is operating very inefficient. -2
  • The TTM is -21.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-26.4%TTM-21.0%-5.4%
TTM-21.0%YOY-41.3%+20.3%
TTM-21.0%5Y-36.5%+15.5%
5Y-36.5%10Y-7.6%-28.9%
1.2.2. Operating Ratio

Measures how efficient Acorda is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.28 means that the operating costs are $1.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acorda Therapeutics Inc:

  • The MRQ is 1.279. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.214. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.279TTM1.214+0.065
TTM1.214YOY1.460-0.246
TTM1.2145Y1.522-0.308
5Y1.52210Y1.193+0.329

1.3. Liquidity of Acorda Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Acorda is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.59 means the company has $1.59 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acorda Therapeutics Inc:

  • The MRQ is 1.593. The company is able to pay all its short-term debts. +1
  • The TTM is 1.963. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.593TTM1.963-0.371
TTM1.963YOY1.802+0.162
TTM1.9635Y2.171-0.208
5Y2.17110Y3.118-0.947
1.3.2. Quick Ratio

Measures if Acorda is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.96 means the company can pay off $0.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acorda Therapeutics Inc:

  • The MRQ is 0.960. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.181. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.960TTM1.181-0.221
TTM1.181YOY0.966+0.214
TTM1.1815Y1.841-0.660
5Y1.84110Y3.422-1.581

1.4. Solvency of Acorda Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Acorda assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acorda to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.84 means that Acorda assets are financed with 83.9% credit (debt) and the remaining percentage (100% - 83.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acorda Therapeutics Inc:

  • The MRQ is 0.839. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.803. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.839TTM0.803+0.036
TTM0.803YOY0.740+0.063
TTM0.8035Y0.668+0.135
5Y0.66810Y0.581+0.087
1.4.2. Debt to Equity Ratio

Measures if Acorda is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 521.4% means that company has $5.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acorda Therapeutics Inc:

  • The MRQ is 5.214. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.171. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ5.214TTM4.171+1.043
TTM4.171YOY3.038+1.133
TTM4.1715Y2.358+1.813
5Y2.35810Y1.637+0.721

2. Market Valuation of Acorda Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acorda generates.

  • Above 15 is considered overpriced but always compare Acorda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.52 means the investor is paying $-0.52 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acorda Therapeutics Inc:

  • The EOD is -0.416. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.524. Based on the earnings, the company is expensive. -2
  • The TTM is -0.238. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.416MRQ-0.524+0.108
MRQ-0.524TTM-0.238-0.286
TTM-0.238YOY-0.017-0.221
TTM-0.2385Y-0.044-0.194
5Y-0.04410Y1.214-1.258
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acorda Therapeutics Inc:

  • The EOD is 0.501. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 0.630. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 0.075. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.501MRQ0.630-0.129
MRQ0.630TTM0.075+0.555
TTM0.075YOY0.034+0.041
TTM0.0755Y-0.009+0.084
5Y-0.00910Y0.487-0.496
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Acorda is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Acorda Therapeutics Inc:

  • The EOD is 0.251. Based on the equity, the company is cheap. +2
  • The MRQ is 0.316. Based on the equity, the company is cheap. +2
  • The TTM is 0.145. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.251MRQ0.316-0.065
MRQ0.316TTM0.145+0.170
TTM0.145YOY0.012+0.134
TTM0.1455Y0.042+0.104
5Y0.04210Y0.050-0.009
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acorda Therapeutics Inc.

3.1. Institutions holding Acorda Therapeutics Inc

Institutions are holding 13.223% of the shares of Acorda Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Davidson Kempner Capital Management LP4.43970.01195514500
2023-12-31Renaissance Technologies Corp3.68420.001145761-300-0.6513
2023-09-30Acadian Asset Management LLC2.71240.0021336913339111130.3333
2023-09-30Vanguard Group Inc0.8642010734107340
2023-12-31BlackRock Inc0.533606628-150-2.213
2023-09-30Wells Fargo & Co0.30110374000
2023-09-30Deutsche Bank AG0.13690170000
2023-09-30Morgan Stanley - Brokerage Accounts0.094701176-100-7.837
2023-09-30UBS Group AG0.010801341340
2023-09-30Tower Research Capital LLC0.003304133412.5
2023-09-30First Manhattan Co. LLC0.00020300
2023-09-30JPMorgan Chase & Co0.0002021100
2023-09-30Advisor Group Holdings, Inc.0.0002021100
2023-09-30Qube Research & Technologies0.00010110
2023-09-30Royal Bank of Canada000-516-100
2023-09-30FMR Inc000-1-100
2023-09-30Group One Trading, LP000-204-100
Total 12.78160.0151158758+43024+27.1%

3.2. Funds holding Acorda Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.84040.00011043800
2024-02-29Vanguard Total Stock Mkt Idx Inv0.6780842240.0475
2024-01-31Fidelity Extended Market Index0.53810.0003668400
2023-12-31Bridgeway Ultra-Small Company Market0.30880.03383600
2024-01-31Fidelity Series Total Market Index0.11460142300
2023-12-31Northern Trust Extended Eq Market Idx0.08290.0003103000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.08290.0003103000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06050.000275100
2023-09-30BlackRock Extended Mkt Composite0.05560.000169100
2023-12-31BlackRock Extended Equity Market K0.04850.0001603-1-0.1656
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04850.000260310.1661
2024-01-31Fidelity Total Market Index0.0419052000
2024-02-29iShares Core S&P Total US Stock Mkt ETF0.0313038900
2024-01-31Fidelity Nasdaq Composite Index0.0246030600
2023-12-31SSgA U.S. Extended Market Index Class I0.02110.000126200
2024-02-29State St US Extended Mkt Indx NL Cl C0.02110.000226200
2023-12-31BlackRock U.S. Equity Market F0.0151018700
2023-12-31SSgA U.S. Total Market Index Strategy0.0061076-2-2.5641
2023-12-31Extended Equity Market Fund M0.0060.00017545.6338
2024-01-31Spartan Total Market Index Pool E0.004906100
Total 3.03090.03237649+6+0.0%

3.3. Insider Transactions

Insiders are holding 0.689% of the shares of Acorda Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-03-16Ron CohenBUY50712
2022-03-17Ron CohenSELL11434

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Acorda Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---7.174-3.383-53%-17.855+149%-21.724+203%-7.215+1%
Book Value Per Share--47.46651.723-8%89.034-47%188.943-75%323.074-85%
Current Ratio--1.5931.963-19%1.802-12%2.171-27%3.118-49%
Debt To Asset Ratio--0.8390.803+5%0.740+13%0.668+26%0.581+44%
Debt To Equity Ratio--5.2144.171+25%3.038+72%2.358+121%1.637+218%
Dividend Per Share----0%-0%0.045-100%0.613-100%
Eps---7.156-3.376-53%-21.259+197%-22.925+220%-14.968+109%
Free Cash Flow Per Share--5.948-1.213+120%-5.436+191%-15.492+360%-14.672+347%
Free Cash Flow To Equity Per Share--0.406-2.598+740%-20.324+5109%-24.100+6039%-9.214+2371%
Gross Profit Margin--1.0001.0000%1.0000%1.000+0%1.355-26%
Intrinsic Value_10Y_max--267.966--------
Intrinsic Value_10Y_min---573.345--------
Intrinsic Value_1Y_max---13.732--------
Intrinsic Value_1Y_min---58.854--------
Intrinsic Value_3Y_max---10.330--------
Intrinsic Value_3Y_min---176.667--------
Intrinsic Value_5Y_max--30.362--------
Intrinsic Value_5Y_min---293.395--------
Market Cap14793411.000-26%18619079.0009295678.784+100%1479589.520+1158%5795744.977+221%20799319.343-10%
Net Profit Margin---0.321-0.196-39%-0.890+178%-0.779+143%-0.406+27%
Operating Margin---0.264-0.210-20%-0.413+57%-0.365+38%-0.076-71%
Operating Ratio--1.2791.214+5%1.460-12%1.522-16%1.193+7%
Pb Ratio0.251-26%0.3160.145+117%0.012+2599%0.042+656%0.050+527%
Pe Ratio-0.416+21%-0.524-0.238-55%-0.017-97%-0.044-92%1.214-143%
Price Per Share11.910-26%14.9907.338+104%1.191+1158%4.634+223%16.730-10%
Price To Free Cash Flow Ratio0.501-26%0.6300.075+738%0.034+1753%-0.009+101%0.487+29%
Price To Total Gains Ratio-1.660+21%-2.089-0.970-54%-0.088-96%-0.242-88%-0.207-90%
Quick Ratio--0.9601.181-19%0.966-1%1.841-48%3.422-72%
Return On Assets---0.024-0.012-52%-0.063+161%-0.044+83%-0.025+3%
Return On Equity---0.151-0.076-50%-0.261+73%-0.152+1%-0.083-45%
Total Gains Per Share---7.174-3.383-53%-17.855+149%-21.679+202%-6.602-8%
Usd Book Value--58957000.00074351750.000-21%110589750.000-47%238330500.000-75%403067975.610-85%
Usd Book Value Change Per Share---7.174-3.383-53%-17.855+149%-21.724+203%-7.215+1%
Usd Book Value Per Share--47.46651.723-8%89.034-47%188.943-75%323.074-85%
Usd Dividend Per Share----0%-0%0.045-100%0.613-100%
Usd Eps---7.156-3.376-53%-21.259+197%-22.925+220%-14.968+109%
Usd Free Cash Flow--7388000.000-526500.000+107%-6752500.000+191%-19060650.000+358%-18135341.463+345%
Usd Free Cash Flow Per Share--5.948-1.213+120%-5.436+191%-15.492+360%-14.672+347%
Usd Free Cash Flow To Equity Per Share--0.406-2.598+740%-20.324+5109%-24.100+6039%-9.214+2371%
Usd Market Cap14793411.000-26%18619079.0009295678.784+100%1479589.520+1158%5795744.977+221%20799319.343-10%
Usd Price Per Share11.910-26%14.9907.338+104%1.191+1158%4.634+223%16.730-10%
Usd Profit---8888000.000-3987750.000-55%-26406250.000+197%-28396350.000+219%-18553682.927+109%
Usd Revenue--27715000.00027780000.0000%31015750.000-11%37090600.000-25%81251390.244-66%
Usd Total Gains Per Share---7.174-3.383-53%-17.855+149%-21.679+202%-6.602-8%
 EOD+4 -4MRQTTM+9 -24YOY+21 -125Y+22 -1410Y+14 -22

4.2. Fundamental Score

Let's check the fundamental score of Acorda Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.416
Price to Book Ratio (EOD)Between0-10.251
Net Profit Margin (MRQ)Greater than0-0.321
Operating Margin (MRQ)Greater than0-0.264
Quick Ratio (MRQ)Greater than10.960
Current Ratio (MRQ)Greater than11.593
Debt to Asset Ratio (MRQ)Less than10.839
Debt to Equity Ratio (MRQ)Less than15.214
Return on Equity (MRQ)Greater than0.15-0.151
Return on Assets (MRQ)Greater than0.05-0.024
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Acorda Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.664
Ma 20Greater thanMa 5012.787
Ma 50Greater thanMa 10014.394
Ma 100Greater thanMa 20013.425
OpenGreater thanClose12.400
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets366,344
Total Liabilities307,387
Total Stockholder Equity58,957
 As reported
Total Liabilities 307,387
Total Stockholder Equity+ 58,957
Total Assets = 366,344

Assets

Total Assets366,344
Total Current Assets73,728
Long-term Assets292,616
Total Current Assets
Cash And Cash Equivalents 32,468
Net Receivables 11,977
Inventory 17,942
Other Current Assets 10,480
Total Current Assets  (as reported)73,728
Total Current Assets  (calculated)72,867
+/- 861
Long-term Assets
Property Plant Equipment 6,706
Intangible Assets 282,006
Long-term Assets Other 3,904
Long-term Assets  (as reported)292,616
Long-term Assets  (calculated)292,616
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities46,294
Long-term Liabilities261,093
Total Stockholder Equity58,957
Total Current Liabilities
Short-term Debt 1,578
Accounts payable 12,330
Other Current Liabilities 31,921
Total Current Liabilities  (as reported)46,294
Total Current Liabilities  (calculated)45,829
+/- 465
Long-term Liabilities
Long term Debt 181,043
Capital Lease Obligations 5,046
Long-term Liabilities Other 38,038
Long-term Liabilities  (as reported)261,093
Long-term Liabilities  (calculated)224,127
+/- 36,966
Total Stockholder Equity
Common Stock1
Retained Earnings -971,366
Accumulated Other Comprehensive Income 717
Other Stockholders Equity 1,029,605
Total Stockholder Equity (as reported)58,957
Total Stockholder Equity (calculated)58,957
+/-0
Other
Capital Stock1
Cash and Short Term Investments 32,468
Common Stock Shares Outstanding 1,242
Current Deferred Revenue465
Liabilities and Stockholders Equity 366,344
Net Debt 153,621
Net Invested Capital 181,043
Net Working Capital 27,434
Property Plant and Equipment Gross 6,706
Short Long Term Debt Total 186,089



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-11-042013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302004-12-312003-12-312003-09-30
> Total Assets 
57,024
45,960
30,982
25,543
33,912
49,553
44,193
40,317
84,368
68,086
133,908
136,858
127,306
196,130
184,398
297,979
281,501
261,666
368,170
337,597
319,471
318,216
295,988
331,421
342,101
336,207
336,095
351,098
379,488
386,052
403,053
410,453
565,332
565,423
575,906
586,647
586,647
607,127
611,887
943,317
972,767
1,080,679
1,098,982
1,100,550
1,100,278
1,116,343
1,211,694
1,357,656
1,318,368
1,342,335
1,319,842
1,332,442
1,345,057
1,197,969
1,187,073
1,250,616
1,311,085
1,299,666
1,233,938
1,197,462
879,913
799,718
753,827
728,210
710,593
632,680
584,048
491,498
466,087
455,470
424,138
406,312
393,339
395,595
374,906
364,696
366,344
366,344364,696374,906395,595393,339406,312424,138455,470466,087491,498584,048632,680710,593728,210753,827799,718879,9131,197,4621,233,9381,299,6661,311,0851,250,6161,187,0731,197,9691,345,0571,332,4421,319,8421,342,3351,318,3681,357,6561,211,6941,116,3431,100,2781,100,5501,098,9821,080,679972,767943,317611,887607,127586,647586,647575,906565,423565,332410,453403,053386,052379,488351,098336,095336,207342,101331,421295,988318,216319,471337,597368,170261,666281,501297,979184,398196,130127,306136,858133,90868,08684,36840,31744,19349,55333,91225,54330,98245,96057,024
   > Total Current Assets 
53,912
0
0
17,392
25,464
41,440
36,344
32,878
72,233
55,988
117,053
120,103
111,034
175,261
164,202
278,410
262,048
242,140
341,033
311,320
293,280
285,993
263,781
299,513
311,169
305,680
305,853
334,373
360,942
347,714
327,237
379,263
397,335
395,479
409,020
415,932
387,803
441,318
448,658
804,532
838,016
409,138
423,836
427,633
429,568
453,445
556,554
276,409
240,903
277,057
252,552
260,010
307,815
441,698
428,188
494,552
546,595
528,107
417,904
358,370
314,337
201,113
168,285
158,024
151,814
221,335
189,719
112,943
97,069
102,157
80,455
76,522
71,692
82,115
68,094
64,914
73,728
73,72864,91468,09482,11571,69276,52280,455102,15797,069112,943189,719221,335151,814158,024168,285201,113314,337358,370417,904528,107546,595494,552428,188441,698307,815260,010252,552277,057240,903276,409556,554453,445429,568427,633423,836409,138838,016804,532448,658441,318387,803415,932409,020395,479397,335379,263327,237347,714360,942334,373305,853305,680311,169299,513263,781285,993293,280311,320341,033242,140262,048278,410164,202175,261111,034120,103117,05355,98872,23332,87836,34441,44025,46417,3920053,912
       Cash And Cash Equivalents 
8,033
8,965
11,729
3,581
11,761
25,961
23,684
11,921
18,101
13,173
35,474
20,626
16,810
67,435
34,253
79,785
29,613
36,118
32,697
25,708
47,314
85,732
75,669
82,405
34,641
78,457
48,635
44,385
57,954
55,300
64,717
40,026
41,876
34,687
42,702
46,266
46,266
48,037
44,355
274,599
53,341
182,170
61,515
76,197
89,837
153,204
431,414
137,400
127,940
158,537
133,619
141,135
192,496
307,068
226,276
243,345
321,011
293,564
197,093
147,648
119,521
62,085
32,417
40,577
57,910
71,369
116,773
45,714
36,168
45,634
31,873
23,127
20,696
37,536
30,255
25,270
32,468
32,46825,27030,25537,53620,69623,12731,87345,63436,16845,714116,77371,36957,91040,57732,41762,085119,521147,648197,093293,564321,011243,345226,276307,068192,496141,135133,619158,537127,940137,400431,414153,20489,83776,19761,515182,17053,341274,59944,35548,03746,26646,26642,70234,68741,87640,02664,71755,30057,95444,38548,63578,45734,64182,40575,66985,73247,31425,70832,69736,11829,61379,78534,25367,43516,81020,62635,47413,17318,10111,92123,68425,96111,7613,58111,7298,9658,033
       Short-term Investments 
43,836
32,505
9,653
5,160
2,001
3,990
500
6,440
35,656
32,014
69,207
84,507
78,310
92,858
114,757
183,460
216,435
189,834
179,697
266,706
224,778
157,856
140,770
163,412
205,389
146,890
179,565
224,428
237,953
222,945
191,133
192,204
191,949
248,659
260,627
246,043
246,043
225,891
226,065
331,254
713,100
125,448
238,182
225,523
233,593
200,101
190
0
0
79
61
0
68
410
106,767
148,371
139,935
151,989
146,157
149,242
133,636
63,754
50,477
25,410
5,347
0
0
0
0
0
0
0
0
0
0
0
0
0000000000005,34725,41050,47763,754133,636149,242146,157151,989139,935148,371106,767410680617900190200,101233,593225,523238,182125,448713,100331,254226,065225,891246,043246,043260,627248,659191,949192,204191,133222,945237,953224,428179,565146,890205,389163,412140,770157,856224,778266,706179,697189,834216,435183,460114,75792,85878,31084,50769,20732,01435,6566,4405003,9902,0015,1609,65332,50543,836
       Net Receivables 
164
0
0
820
744
784
1,420
3,946
9,389
2,373
3,638
3,806
4,266
4,120
4,957
4,017
4,622
4,603
115,470
4,386
5,739
8,083
18,065
18,369
22,272
23,795
23,416
20,608
22,828
21,526
23,607
23,227
26,327
23,288
27,055
24,998
50,098
30,784
29,265
27,027
24,792
32,211
30,551
29,797
31,755
31,466
41,623
45,886
48,575
52,239
50,238
55,626
53,825
81,403
50,787
64,360
51,461
23,430
20,652
21,010
17,553
22,083
14,969
14,773
13,385
20,193
17,295
14,010
13,587
17,002
11,990
14,270
14,690
13,866
9,190
13,390
11,977
11,97713,3909,19013,86614,69014,27011,99017,00213,58714,01017,29520,19313,38514,77314,96922,08317,55321,01020,65223,43051,46164,36050,78781,40353,82555,62650,23852,23948,57545,88641,62331,46631,75529,79730,55132,21124,79227,02729,26530,78450,09824,99827,05523,28826,32723,22723,60721,52622,82820,60823,41623,79522,27218,36918,0658,0835,7394,386115,4704,6034,6224,0174,9574,1204,2663,8063,6382,3739,3893,9461,42078474482000164
       Inventory 
860
0
423
4,954
6,757
6,338
7,351
7,142
6,221
5,094
5,996
7,178
7,724
6,743
6,475
7,454
6,144
5,064
6,072
5,775
6,893
23,612
20,015
26,182
38,418
44,795
42,145
29,769
28,382
28,659
29,413
19,240
20,957
28,586
31,690
26,245
25,574
26,172
31,154
31,401
27,215
26,837
45,831
49,202
46,838
36,476
39,667
55,553
40,935
43,135
46,054
43,914
39,870
37,501
27,662
21,147
10,800
29,014
31,465
28,086
27,396
25,221
25,566
32,940
30,120
28,677
27,415
25,355
20,595
18,548
14,836
15,321
15,252
12,752
13,465
14,797
17,942
17,94214,79713,46512,75215,25215,32114,83618,54820,59525,35527,41528,67730,12032,94025,56625,22127,39628,08631,46529,01410,80021,14727,66237,50139,87043,91446,05443,13540,93555,55339,66736,47646,83849,20245,83126,83727,21531,40131,15426,17225,57426,24531,69028,58620,95719,24029,41328,65928,38229,76942,14544,79538,41826,18220,01523,6126,8935,7756,0725,0646,1447,4546,4756,7437,7247,1785,9965,0946,2217,1427,3516,3386,7574,9544230860
       Other Current Assets 
1,020
1,115
1,069
1,155
1,713
2,281
1,755
1,441
1,186
1,192
905
1,436
1,293
970
952
976
1,606
1,840
219,491
301,159
3,981
254,298
225,701
254,962
3,734
237,090
240,292
7,781
6,988
297,529
274,217
336,796
16,863
18,700
17,896
15,311
16,858
17,135
16,087
18,396
19,568
24,052
27,288
27,593
22,578
30,070
31,577
24,325
20,502
18,746
18,241
14,935
17,224
15,726
16,696
17,329
23,388
30,110
22,537
12,384
16,230
15,134
31,681
31,308
31,853
16,384
15,182
14,981
13,366
7,573
1,856
10,691
7,822
11,077
4,070
10,629
10,480
10,48010,6294,07011,0777,82210,6911,8567,57313,36614,98115,18216,38431,85331,30831,68115,13416,23012,38422,53730,11023,38817,32916,69615,72617,22414,93518,24118,74620,50224,32531,57730,07022,57827,59327,28824,05219,56818,39616,08717,13516,85815,31117,89618,70016,863336,796274,217297,5296,9887,781240,292237,0903,734254,962225,701254,2983,981301,159219,4911,8401,6069769529701,2931,4369051,1921,1861,4411,7552,2811,7131,1551,0691,1151,020
   > Long-term Assets 
3,112
0
0
8,151
8,448
8,113
7,849
7,439
12,135
12,098
16,855
16,755
16,273
20,868
20,197
19,569
19,453
19,525
27,137
26,277
26,190
32,223
32,207
31,908
30,933
30,527
30,242
16,725
18,546
38,338
75,816
31,190
167,997
169,944
166,886
170,715
239,794
165,809
163,229
138,785
134,751
671,541
675,146
672,917
670,710
662,898
655,140
1,081,247
1,077,465
1,065,278
1,067,290
1,072,432
1,037,242
756,271
758,885
756,064
764,490
771,559
816,034
839,092
565,576
598,605
585,542
570,186
558,779
411,345
394,329
378,555
369,018
353,313
343,683
329,790
321,647
313,480
306,812
299,782
292,616
292,616299,782306,812313,480321,647329,790343,683353,313369,018378,555394,329411,345558,779570,186585,542598,605565,576839,092816,034771,559764,490756,064758,885756,2711,037,2421,072,4321,067,2901,065,2781,077,4651,081,247655,140662,898670,710672,917675,146671,541134,751138,785163,229165,809239,794170,715166,886169,944167,99731,19075,81638,33818,54616,72530,24230,52730,93331,90832,20732,22326,19026,27727,13719,52519,45319,56920,19720,86816,27316,75516,85512,09812,1357,4397,8498,1138,4488,151003,112
       Property Plant Equipment 
3,001
3,093
2,547
1,905
1,707
1,577
1,482
1,277
1,223
1,420
1,427
1,741
1,652
1,867
1,826
1,869
2,348
2,780
3,044
3,344
1,891
2,087
2,788
3,321
3,203
3,594
3,543
3,595
3,858
6,521
14,290
16,437
16,706
16,936
17,740
17,752
16,525
16,525
16,440
15,823
17,089
46,090
45,919
44,453
42,415
40,204
38,027
36,754
35,777
34,310
37,132
37,368
36,484
36,669
39,023
42,524
52,061
60,519
109,834
139,331
155,260
165,977
164,950
162,851
159,060
25,744
16,464
14,664
12,877
11,133
9,255
8,815
8,366
7,890
7,412
6,928
6,706
6,7066,9287,4127,8908,3668,8159,25511,13312,87714,66416,46425,744159,060162,851164,950165,977155,260139,331109,83460,51952,06142,52439,02336,66936,48437,36837,13234,31035,77736,75438,02740,20442,41544,45345,91946,09017,08915,82316,44016,52516,52517,75217,74016,93616,70616,43714,2906,5213,8583,5953,5433,5943,2033,3212,7882,0871,8913,3443,0442,7802,3481,8691,8261,8671,6521,7411,4271,4201,2231,2771,4821,5771,7071,9052,5473,0933,001
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
182,952
182,952
182,952
183,636
183,636
183,636
284,504
284,029
280,599
278,069
281,896
285,317
286,611
289,577
284,100
283,435
282,059
280,128
281,467
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000281,467280,128282,059283,435284,100289,577286,611285,317281,896278,069280,599284,029284,504183,636183,636183,636182,952182,952182,95200000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,046
47,118
86,434
99,363
41,559
29,050
57,069
93,299
93,299
101,732
121,855
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000121,855101,73293,29993,29957,06929,05041,55999,36386,43447,11817,04600000000000000000000000000000
       Intangible Assets 
0
0
3,386
6,137
5,952
5,768
5,583
5,398
10,178
9,950
14,723
14,333
13,944
18,348
17,751
17,155
16,565
16,245
15,924
15,603
17,149
23,180
22,657
22,013
21,336
20,707
20,502
7,053
8,769
8,950
8,755
9,279
9,319
9,446
9,875
17,590
17,590
17,459
17,959
17,281
16,865
432,822
432,155
431,759
431,279
430,856
430,491
751,524
749,415
742,242
740,838
742,704
705,141
430,603
429,792
428,762
428,575
428,570
425,777
418,000
410,023
402,329
390,311
382,505
374,743
366,981
359,245
351,481
343,731
335,980
328,228
320,472
312,779
305,087
297,393
289,700
282,006
282,006289,700297,393305,087312,779320,472328,228335,980343,731351,481359,245366,981374,743382,505390,311402,329410,023418,000425,777428,570428,575428,762429,792430,603705,141742,704740,838742,242749,415751,524430,491430,856431,279431,759432,155432,82216,86517,28117,95917,45917,59017,5909,8759,4469,3199,2798,7558,9508,7697,05320,50220,70721,33622,01322,65723,18017,14915,60315,92416,24516,56517,15517,75118,34813,94414,33314,7239,95010,1785,3985,5835,7685,9526,1373,38600
       Long-term Assets Other 
112
0
0
109
789
768
784
764
734
728
705
681
677
654
619
545
539
501
8,169
7,330
7,150
6,956
6,762
6,574
6,394
6,226
6,197
6,077
5,919
5,821
5,653
5,474
-94,118
-36,497
-24,167
-52,361
352
-88,773
-97,380
-111,511
10,039
9,677
14,120
13,753
13,380
8,202
2,986
8,465
8,244
8,127
11,251
10,464
10,300
2,388
493
678
419
411
295
294
293
30,299
30,281
24,830
24,976
18,620
18,620
12,410
12,410
6,200
6,200
503
502
-42,783
2,007
3,154
3,904
3,9043,1542,007-42,7835025036,2006,20012,41012,41018,62018,62024,97624,83030,28130,2992932942954114196784932,38810,30010,46411,2518,1278,2448,4652,9868,20213,38013,75314,1209,67710,039-111,511-97,380-88,773352-52,361-24,167-36,497-94,1185,4745,6535,8215,9196,0776,1976,2266,3946,5746,7626,9567,1507,3308,16950153954561965467768170572873476478476878910900112
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,380
6,215
6,050
0
5,759
5,600
0
5,283
5,125
4,967
106,444
106,194
105,944
106,057
112,159
112,159
112,000
88,742
88,583
-20,345
3,381
3,223
3,064
5,034
15,020
4,717
2,430
2,272
2,113
1,955
1,796
1,638
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,6381,7961,9552,1132,2722,4304,71715,0205,0343,0643,2233,381-20,34588,58388,742112,000112,159112,159106,057105,944106,194106,4444,9675,1255,28305,6005,75906,0506,2156,3800000000000000000000000
> Total Liabilities 
39,541
15,919
25,189
127,212
150,448
49,835
46,391
48,711
65,699
54,497
63,227
61,840
63,874
69,428
71,986
73,634
74,343
70,174
196,373
181,320
182,138
194,769
173,289
189,059
190,841
181,419
173,343
164,182
174,279
166,958
173,403
164,986
179,411
173,784
171,108
160,256
586,647
166,774
161,367
442,938
449,854
540,424
549,962
540,266
525,390
513,318
527,682
676,114
651,602
678,124
643,715
642,722
665,067
677,982
637,148
643,981
712,460
687,683
667,352
652,625
598,571
488,898
447,153
437,306
396,085
394,725
377,769
301,017
301,612
304,333
296,589
318,405
317,573
301,973
297,946
296,828
307,387
307,387296,828297,946301,973317,573318,405296,589304,333301,612301,017377,769394,725396,085437,306447,153488,898598,571652,625667,352687,683712,460643,981637,148677,982665,067642,722643,715678,124651,602676,114527,682513,318525,390540,266549,962540,424449,854442,938161,367166,774586,647160,256171,108173,784179,411164,986173,403166,958174,279164,182173,343181,419190,841189,059173,289194,769182,138181,320196,37370,17474,34373,63471,98669,42863,87461,84063,22754,49765,69948,71146,39149,835150,448127,21225,18915,91939,541
   > Total Current Liabilities 
6,836
7,381
15,872
29,595
35,858
26,554
23,965
27,443
38,910
28,778
38,229
36,659
39,264
45,195
46,337
48,464
54,603
50,630
67,586
64,889
72,900
89,162
70,766
89,448
94,250
88,074
82,576
74,437
87,343
82,057
88,433
82,039
98,871
96,864
96,860
88,258
88,258
96,643
94,705
94,612
100,921
114,383
122,165
111,671
93,239
90,592
105,004
136,125
118,122
147,901
119,335
107,141
109,738
143,960
117,359
120,871
135,708
140,256
97,287
93,951
91,992
86,386
70,628
138,230
138,750
137,252
133,051
68,269
68,271
54,025
46,000
41,120
42,023
37,950
34,739
30,385
46,294
46,29430,38534,73937,95042,02341,12046,00054,02568,27168,269133,051137,252138,750138,23070,62886,38691,99293,95197,287140,256135,708120,871117,359143,960109,738107,141119,335147,901118,122136,125105,00490,59293,239111,671122,165114,383100,92194,61294,70596,64388,25888,25896,86096,86498,87182,03988,43382,05787,34374,43782,57688,07494,25089,44870,76689,16272,90064,88967,58650,63054,60348,46446,33745,19539,26436,65938,22928,77838,91027,44323,96526,55435,85829,59515,8727,3816,836
       Short-term Debt 
317
0
0
2,347
1,068
1,041
1,020
1,011
1,044
995
732
463
188
13,261
9,738
11,501
13,994
17,945
-26,128
6,402
0
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,144
1,117
1,126
1,134
7,021
754
615
636
645
663
629
624
616
8,062
8,256
8,283
8,349
8,438
75,374
75,943
76,575
74,727
10,708
9,316
8,186
7,036
1,347
1,454
1,545
1,556
1,567
1,578
1,5781,5671,5561,5451,4541,3477,0368,1869,31610,70874,72776,57575,94375,3748,4388,3498,2838,2568,0626166246296636456366157547,0211,1341,1261,1171,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,1441,14406,402-26,12817,94513,99411,5019,73813,2611884637329951,0441,0111,0201,0411,0682,34700317
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,144
0
0
0
1,169
1,117
1,126
1,134
7,021
754
328,712
636
645
663
629
624
616
604
612
587
3,814
592
67,478
68,050
68,631
68,529
0
0
0
0
0
0
0
0
0
0
000000000068,52968,63168,05067,4785923,814587612604616624629663645636328,7127547,0211,1341,1261,1171,1690001,14400000000000000000000000000000000000000000
       Accounts payable 
3,602
2,659
1,929
1,810
4,134
2,052
2,944
2,162
3,315
1,954
2,809
7,809
6,676
5,905
10,023
12,250
10,125
7,317
33,509
21,932
11,613
42,133
24,475
43,167
16,961
44,958
41,704
13,943
21,393
40,497
47,926
41,703
58,261
55,863
55,400
45,827
53,491
53,491
52,837
54,724
60,292
73,869
82,094
72,482
82,477
80,366
94,830
125,942
107,931
131,823
109,524
97,469
100,045
127,495
110,160
113,161
127,370
125,741
71,873
71,318
70,011
65,335
49,041
52,110
51,792
50,322
9,488
17,483
15,500
11,815
8,768
7,958
11,505
10,087
2,854
3,175
12,330
12,3303,1752,85410,08711,5057,9588,76811,81515,50017,4839,48850,32251,79252,11049,04165,33570,01171,31871,873125,741127,370113,161110,160127,495100,04597,469109,524131,823107,931125,94294,83080,36682,47772,48282,09473,86960,29254,72452,83753,49153,49145,82755,40055,86358,26141,70347,92640,49721,39313,94341,70444,95816,96143,16724,47542,13311,61321,93233,5097,31710,12512,25010,0235,9056,6767,8092,8091,9543,3152,1622,9442,0524,1341,8101,9292,6593,602
       Other Current Liabilities 
2,861
4,398
13,641
9,792
13,920
6,945
5,689
7,963
14,109
7,155
15,652
8,814
10,563
2,537
1,880
1,338
6,181
0
26,819
27,126
21,154
6,749
6,552
6,381
35,419
1,979
1,797
20,974
25,150
1,204
1,315
1,335
1,134
1,180
1,174
1,009
41,147
861
450
225
913
893
749
585
561
25
73,475
96,388
89,374
101,913
88,146
77,503
78,304
6,763
6,536
7,081
7,714
13,899
17,352
14,377
13,698
12,702
13,149
10,746
11,015
10,355
10,713
11,272
9,297
6,389
30,196
31,815
29,064
25,934
30,329
25,095
31,921
31,92125,09530,32925,93429,06431,81530,1966,3899,29711,27210,71310,35511,01510,74613,14912,70213,69814,37717,35213,8997,7147,0816,5366,76378,30477,50388,146101,91389,37496,38873,4752556158574989391322545086141,1471,0091,1741,1801,1341,3351,3151,20425,15020,9741,7971,97935,4196,3816,5526,74921,15427,12626,81906,1811,3381,8802,53710,5638,81415,6527,15514,1097,9635,6896,94513,9209,79213,6414,3982,861
   > Long-term Liabilities 
8,525
0
0
97,617
114,590
23,282
22,427
21,268
26,790
25,719
24,999
25,181
24,610
24,232
25,649
25,170
19,740
19,544
128,787
116,431
109,238
105,607
102,523
99,611
96,591
93,345
90,767
89,745
86,936
84,901
84,970
82,947
80,540
76,920
74,248
71,998
69,984
70,131
66,662
348,326
348,933
426,041
427,797
428,595
432,151
422,726
422,678
539,989
533,480
530,223
524,380
535,581
555,329
534,022
519,789
523,110
576,752
547,427
570,065
558,674
506,579
402,512
376,525
299,076
257,335
257,473
244,718
232,748
233,341
250,308
250,589
277,285
275,550
264,023
263,207
266,443
261,093
261,093266,443263,207264,023275,550277,285250,589250,308233,341232,748244,718257,473257,335299,076376,525402,512506,579558,674570,065547,427576,752523,110519,789534,022555,329535,581524,380530,223533,480539,989422,678422,726432,151428,595427,797426,041348,933348,32666,66270,13169,98471,99874,24876,92080,54082,94784,97084,90186,93689,74590,76793,34596,59199,611102,523105,607109,238116,431128,78719,54419,74025,17025,64924,23224,61025,18124,99925,71926,79021,26822,42723,282114,59097,617008,525
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,061
10,507
9,772
8,419
8,122
7,801
7,128
6,034
5,702
5,452
5,355
4,024
3,918
3,855
3,721
3,721
2,455
286,341
287,998
289,883
290,665
292,612
294,583
296,576
292,624
294,854
297,111
324,030
326,366
328,097
331,585
334,475
337,128
338,377
340,833
343,140
345,853
349,017
350,899
218,269
220,062
157,288
161,600
166,174
168,374
172,327
0
0
0
0
0
0
0
0
0
000000000172,327168,374166,174161,600157,288220,062218,269350,899349,017345,853343,140340,833338,377337,128334,475331,585328,097326,366324,030297,111294,854292,624296,576294,583292,612290,665289,883287,998286,3412,4553,7213,7213,8553,9184,0245,3555,4525,7026,0347,1287,8018,1228,4199,77210,50711,0610000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,380
6,215
6,050
0
5,759
5,600
0
5,283
5,125
4,967
106,444
106,194
105,944
106,057
112,159
112,159
112,000
88,742
88,583
-20,345
3,381
3,223
3,064
5,034
15,020
4,717
2,430
2,272
2,113
1,955
1,796
1,638
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,6381,7961,9552,1132,2722,4304,71715,0205,0343,0643,2233,381-20,34588,58388,742112,000112,159112,159106,057105,944106,194106,4444,9675,1255,28305,6005,75906,0506,2156,3800000000000000000000000
       Other Liabilities 
0
0
750
388
549
604
447
532
350
350
363
363
463
463
412
413
337
337
103,845
98,627
96,495
94,138
91,462
89,104
86,819
84,926
82,645
81,944
79,808
78,867
79,268
77,495
75,185
72,896
70,330
68,143
0
66,410
64,207
55,524
60,935
112,273
113,247
112,098
113,000
114,004
117,908
144,058
144,940
113,386
121,884
127,927
125,208
177,088
182,662
184,733
235,919
204,287
197,757
183,891
131,286
161,248
134,706
121,510
77,820
74,099
66,534
56,994
53,678
67,552
64,280
87,414
83,249
92,651
0
86,514
0
086,514092,65183,24987,41464,28067,55253,67856,99466,53474,09977,820121,510134,706161,248131,286183,891197,757204,287235,919184,733182,662177,088125,208127,927121,884113,386144,940144,058117,908114,004113,000112,098113,247112,27360,93555,52464,20766,410068,14370,33072,89675,18577,49579,26878,86779,80881,94482,64584,92686,81989,10491,46294,13896,49598,627103,84533733741341246346336336335035053244760454938875000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91,143
88,786
86,429
84,535
82,271
80,007
77,742
75,478
73,214
70,949
68,685
66,421
64,156
61,892
59,628
59,628
57,363
55,099
52,835
74,455
72,191
69,927
68,345
53,659
51,395
126,944
126,149
125,263
106,321
107,483
124,200
45,857
24,936
37,586
70,656
7,483
5,401
3,069
2,804
68,990
49,272
41,028
23,952
20,309
16,913
15,722
0
0
0
0
0
0
0
0
0
00000000015,72216,91320,30923,95241,02849,27268,9902,8043,0695,4017,48370,65637,58624,93645,857124,200107,483106,321125,263126,149126,94451,39553,65968,34569,92772,19174,45552,83555,09957,36359,62859,62861,89264,15666,42168,68570,94973,21475,47877,74280,00782,27184,53586,42988,78691,1430000000000000000000000
> Total Stockholder Equity
17,484
30,041
5,793
-101,669
-116,536
-283
-2,199
-8,393
18,669
13,589
70,680
75,019
63,433
126,702
112,412
224,344
207,157
191,492
171,797
156,277
137,333
123,447
122,699
142,362
151,261
154,788
162,752
186,916
205,209
219,094
229,650
245,467
385,921
391,639
404,798
426,391
440,353
440,353
450,520
500,379
522,913
540,255
549,020
560,284
574,888
603,025
684,012
671,638
656,862
654,307
666,223
679,816
679,990
519,987
549,925
606,635
598,625
611,983
566,586
544,837
281,342
310,820
306,674
290,904
314,508
237,955
206,279
190,481
164,475
151,137
127,549
87,907
75,766
93,622
76,960
67,868
58,957
58,95767,86876,96093,62275,76687,907127,549151,137164,475190,481206,279237,955314,508290,904306,674310,820281,342544,837566,586611,983598,625606,635549,925519,987679,990679,816666,223654,307656,862671,638684,012603,025574,888560,284549,020540,255522,913500,379450,520440,353440,353426,391404,798391,639385,921245,467229,650219,094205,209186,916162,752154,788151,261142,362122,699123,447137,333156,277171,797191,492207,157224,344112,412126,70263,43375,01970,68013,58918,669-8,393-2,199-283-116,536-101,6695,79330,04117,484
   Common Stock
0
0
0
0
0
20
20
20
24
24
27
28
29
32
33
38
38
38
38
38
38
38
38
39
39
39
39
39
39
39
39
39
40
40
40
41
41
41
41
41
41
42
43
43
43
43
46
46
46
46
47
47
47
46
47
47
47
48
48
48
48
48
48
48
48
9
9
11
11
13
13
24
24
24
24
1
1
1124242424131311119948484848484848484747474647474746464646434343434241414141414140404039393939393939393938383838383838383332292827242420202000000
   Retained Earnings -971,366-962,478-953,097-936,273-955,415-941,561-894,879-870,357-849,789-822,718-799,855-766,403-683,355-690,702-673,281-666,809-732,469-468,934-441,448-393,843-403,439-389,527-435,725-455,108-284,148-258,953-250,757-243,970-240,876-228,152-209,872-209,352-218,557-222,498-223,495-220,410-220,741-232,694-237,379-238,082-238,082-244,274-251,751-255,662-254,523-387,496-397,090-401,635-409,481-422,175-441,043-440,758-440,086-443,757-456,194-449,431-428,317-405,843-386,413-363,085-344,376-324,145-305,289-286,467-270,036-256,306-247,774-239,610-232,061-225,052-217,882-214,986-208,042-198,47500-114,283
   Accumulated Other Comprehensive Income 
-1,378
0
0
-6
-2
-2
-3
6
13
10
97
227
296
576
124
852
813
185
124
236
109
44
9
22
-13
40
112
69
66
-34
-39
69
62
83
54
98
98
37
82
96
166
-74
-91
-60
-43
-119
0
-4,711
-3,615
-12,901
-10,499
-329
6,937
6,858
9,313
4,799
4,113
2,806
1,375
2,617
-636
-1,169
-819
-1,223
-2,286
-2,803
-1,734
-1,833
-1,557
-1,017
-568
738
2,090
628
719
880
717
7178807196282,090738-568-1,017-1,557-1,833-1,734-2,803-2,286-1,223-819-1,169-6362,6171,3752,8064,1134,7999,3136,8586,937-329-10,499-12,901-3,615-4,7110-119-43-60-91-74166968237989854836269-39-34666911240-13229441092361241858138521245762962279710136-3-2-2-600-1,378
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
578,845
586,058
591,649
595,796
603,973
609,312
614,914
621,053
627,069
633,184
640,671
647,507
656,784
670,855
678,686
678,686
688,105
733,265
743,776
761,026
772,892
783,128
793,774
812,782
894,167
904,784
911,540
921,365
937,665
949,344
957,543
968,580
977,881
993,292
999,880
1,005,105
1,008,796
1,011,744
1,015,037
979,388
981,364
983,420
999,762
1,007,790
1,008,497
1,015,659
0
0
0
0
0
0
0
0
0
0000000001,015,6591,008,4971,007,790999,762983,420981,364979,3881,015,0371,011,7441,008,7961,005,105999,880993,292977,881968,580957,543949,344937,665921,365911,540904,784894,167812,782793,774783,128772,892761,026743,776733,265688,105678,686678,686670,855656,784647,507640,671633,184627,069621,053614,914609,312603,973595,796591,649586,058578,8450000000000000000000000
   Treasury Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-329
329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-329
-389
-389
-389
-1,591
-1,976
-1,976
-2,133
-2,185
-638
-638
-638
-638
-638
-638
-638
-638
-638
0
0
0
0
0
0
0
0
0
000000000-638-638-638-638-638-638-638-638-638-2,185-2,133-1,976-1,976-1,591-389-389-389-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329-329329-329000000000000000000000000
   Other Stockholders Equity 
133,144
0
0
96,806
91,501
214,686
215,667
216,632
250,693
253,165
318,330
331,069
333,144
412,560
417,544
547,600
550,683
554,353
558,048
561,846
565,503
572,796
578,845
586,058
591,321
595,467
603,644
608,983
614,585
620,724
626,740
632,855
640,342
647,178
656,455
670,526
37
678,357
687,776
732,936
743,447
760,697
772,563
782,799
793,445
812,453
893,838
904,455
911,211
921,036
937,336
948,955
957,154
968,191
976,290
991,316
997,904
1,002,972
1,006,611
1,011,106
1,014,399
978,750
980,726
982,782
999,124
1,007,152
1,007,859
1,015,021
1,015,810
1,022,498
1,022,983
1,028,706
1,029,067
1,029,243
1,029,314
67,868
1,029,605
1,029,60567,8681,029,3141,029,2431,029,0671,028,7061,022,9831,022,4981,015,8101,015,0211,007,8591,007,152999,124982,782980,726978,7501,014,3991,011,1061,006,6111,002,972997,904991,316976,290968,191957,154948,955937,336921,036911,211904,455893,838812,453793,445782,799772,563760,697743,447732,936687,776678,35737670,526656,455647,178640,342632,855626,740620,724614,585608,983603,644595,467591,321586,058578,845572,796565,503561,846558,048554,353550,683547,600417,544412,560333,144331,069318,330253,165250,693216,632215,667214,68691,50196,80600133,144



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue111,118
Cost of Revenue-14,245
Gross Profit96,87396,873
 
Operating Income (+$)
Gross Profit96,873
Operating Expense-131,546
Operating Income-20,428-34,673
 
Operating Expense (+$)
Research Development5,345
Selling General Administrative93,746
Selling And Marketing Expenses-
Operating Expense131,54699,091
 
Net Interest Income (+$)
Interest Income2,179
Interest Expense-30,866
Other Finance Cost-161
Net Interest Income-28,848
 
Pretax Income (+$)
Operating Income-20,428
Net Interest Income-28,848
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-18,577-51,127
EBIT - interestExpense = -30,866
-15,951
14,915
Interest Expense30,866
Earnings Before Interest and Taxes (EBIT)-12,289
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-18,577
Tax Provision--2,626
Net Income From Continuing Ops-15,951-15,951
Net Income-15,951
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net30,69928,848
 

Technical Analysis of Acorda
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acorda. The general trend of Acorda is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acorda's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acorda Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 12.00 < 14.11 < 14.75.

The bearish price targets are: 11.05 > 10.98 > 9.6.

Tweet this
Acorda Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acorda Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acorda Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acorda Therapeutics Inc. The current macd is -0.57072886.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acorda price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Acorda. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Acorda price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Acorda Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAcorda Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acorda Therapeutics Inc. The current adx is 15.51.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Acorda shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Acorda Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acorda Therapeutics Inc. The current sar is 13.67.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Acorda Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acorda Therapeutics Inc. The current rsi is 39.66. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Acorda Therapeutics Inc Daily Relative Strength Index (RSI) ChartAcorda Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acorda Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acorda price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Acorda Therapeutics Inc Daily Stochastic Oscillator ChartAcorda Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acorda Therapeutics Inc. The current cci is -112.61073464.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Acorda Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAcorda Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acorda Therapeutics Inc. The current cmo is -24.20767708.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Acorda Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAcorda Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acorda Therapeutics Inc. The current willr is -95.6937799.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Acorda Therapeutics Inc Daily Williams %R ChartAcorda Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acorda Therapeutics Inc.

Acorda Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acorda Therapeutics Inc. The current atr is 0.77428977.

Acorda Therapeutics Inc Daily Average True Range (ATR) ChartAcorda Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acorda Therapeutics Inc. The current obv is 11,369,326.

Acorda Therapeutics Inc Daily On-Balance Volume (OBV) ChartAcorda Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acorda Therapeutics Inc. The current mfi is 34.36.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Acorda Therapeutics Inc Daily Money Flow Index (MFI) ChartAcorda Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acorda Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Acorda Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acorda Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.664
Ma 20Greater thanMa 5012.787
Ma 50Greater thanMa 10014.394
Ma 100Greater thanMa 20013.425
OpenGreater thanClose12.400
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Acorda with someone you think should read this too:
  • Are you bullish or bearish on Acorda? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acorda? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acorda Therapeutics Inc

I send you an email if I find something interesting about Acorda Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Acorda Therapeutics Inc.

Receive notifications about Acorda Therapeutics Inc in your mailbox!